Universal reference book for medicines
Name of the preparation: CEFZOXIME J (CEFZOXIME J)

Active substance: ceftizoxime

Type: Third generation cephalosporin

Manufacturer: JODAS EXPOIM (India)
Composition, form of production and packaging
Powder for solution for iv and in / m introduction
white or slightly yellowish, crystalline.

1 f.

ceftizoxime 1 g

1 g - glass bottles (1) - packs of cardboard.


Description of the drug approved by the manufacturer for the printed edition of 2013.


Cephalosporin antibiotic III generation for parenteral administration.
It acts bactericidal, disrupting the synthesis of the cell wall of microorganisms. Resistant to a wide spectrum of beta-lactamases (penicillinases and cephalosporinases), including beta-lactamases I, I, III, and IV types of Richmond and TEM type produced by both gram-positive and Gram-negative aerobes, as well as anaerobes.
Has a wide spectrum of action, which includes various aerobic and anaerobic Gram-positive and Gram-negative microorganisms.

Gram-positive aerobes:

Staphylococcus aureus (including strains that form and do not form penicillinase).

Methicillin-resistant staphylococci are resistant to cephalosporins, including ceftizoxime.

Staphylococcus epidermidis (including strains that form and do not form penicillinase)

Streptococcus agalactiae

Streptococcus pneumoniae

Streptococcus pyogenes

Ceftithoxime is usually inactive in most strains of Enterococcus faecalis (formerly S.faecalis).

Gram-negative aerobes:

Acinetobacter spp.

Enterobacter spp.

Escherichia coli

Haemophilus influenzae (including ampicillin-resistant strains)

Klebsiella pneumoniae

Morganella morganii (formerly Proteus morganii)

Neisseria gonorrhoeae

Proteus mirabilis

Proteus vulgaris

Providencia rettgeri (formerly Proteus rettgeri)

Pseudomonas aeruginosa

Serratia marcescens


Bacteroides spp.

Peptococcus spp.

Peptostreptococcus spp.

Ceftizoxime is usually active against the following microorganisms in vitro, but the clinical significance of these data is unknown.

Gram-positive aerobes:

Corynebacterium diphtheriae

Gram-negative aerobes:

Aeromonas hydrophila

Citrobacter spp.

Moraxella spp.

Neisseria meningitidis

Pasteurella multocida

Providencia stuartii

Salmonella spp.

Shigella spp.

Yersinia enterocolitica


Actinomyces spp.

Bifidobacterium spp.

Clostridium spp.
(most strains of Clostridium difficile are resistant)
Eubacterium spp.
Fusobacterium spp. Propionibacterium spp. Veillonellaspp.

C max after i / m administration in doses of 0.5 and 1 g - 13.7 and 39 mcg / ml, respectively.
TC max -1 h. C max after iv introduction at doses of 2 and 3 g - 110.9 and 174 μg / ml, respectively, TC max - 10 min. T 1/2 after in / m and in / in the introduction - 1.7 h. Communication with blood proteins - 30%. Two hours after intravenous administration in urine, a concentration of more than 6 mg / ml is achieved. Therapeutic concentrations are achieved in various fluids and body tissues: bile, pleural, peritoneal, ascitic and other fluids, bones, gall bladder, heart, prostate gland, uterus; accumulates in saliva, bile and cerebrospinal fluid. In small amounts penetrates into breast milk.
It is excreted by the kidneys in an unchanged form, creating high concentrations in the urine.


Bacterial infections caused by susceptible to ceftizoxime strains of microorganisms:

- Lower respiratory tract infection;

- urinary tract infections;

- Gonorrhea;

- infectious and inflammatory diseases of the pelvic organs;

- intra-abdominal infections (excluding infections caused by enterococci);

- septicemia;

- infections of the skin and subcutaneous tissues (excluding infections caused by enterococci);

- infections of bones and joints (excluding infections caused by enterococci);

- Meningitis.

Cefthysoxime is effective in the treatment of severe infections, incl.
in weakened patients, patients with reduced immunity, neutropenia, mixed aerobic-anaerobic infections resistant to other cephalosporins and aminoglycosides.

In / m, in / in struyno (for 3-5 minutes) or drip.
The IV route is preferred in patients with bacterial septicemia, parenchymal abscess limited (in particular, intra-abdominal abscess), peritonitis, or other severe or life-threatening infections. The dose of the drug, the way of doing it should be determined depending on the patient's condition, the severity of the infection and the sensitivity of the microorganism.
Usually the dose of the drug in adults is 1-2 g every 8-12 hours.

In uncomplicated urinary tract infections - 500 mg every 12 hours IV or / m.
In the treatment of infections caused by Pseudomonas aeruginosa, the dose should be increased, as many strains of Pseudomonas aeruginosa are moderately sensitive to ceftizoxime. In the event that the response to treatment does not occur within the next time, it is necessary to start another therapy.
For infections of other localizations , 1 g every 8-12 h IV or IM.

Heavy or refractory infections - 1 g every 8 h or 2 g every 8-12 h iv or in / m.
If it is necessary to administer 2 g / m dose should be divided and introduced separately into different large muscles.
Infectious-inflammatory diseases of the pelvic organs - 2 g every 8 hours in / in.
In the event that Chlamydia trachomatis is suspected as a causative agent, antibiotics effective against Chlamydia trachomatis should be additionally administered, since ceftizoxime is inactive with respect to this pathogen.
Life-threatening infections - 3-4 g every 8 hours in / in.
There is an experience of administering doses up to 2 g every 4 h.
For treatment of uncomplicated gonorrhea -1 g IM once.

With normal kidney function, doses of 2 to 12 g IV may be given daily, with bacterial septicemia IV, doses of 6-12 g are usually administered for several days, after which the dose is gradually reduced in accordance with the clinical response and laboratory parameters .

Children older than 6 months - 50 mg / kg / day every 6-8 hours. If necessary, the dose may be increased to a total daily dose of 200 mg / kg, but should not exceed the maximum recommended dose in adults for the treatment of severe infections.

If the excretory function of the kidneys is disturbed , correction of the dosing regimen is required depending on the values ​​of creatinine clearance (CK).
After an initial dose of 500 mg or 1 g IV or IM, a dose reduction should be made according to the data in the table:
KC ml / min Less severe infections Life-threatening infections

50-79 500 mg every 8 hours 750 mg-1.5 g every 8 hours

5-49 250-500 mg every 12 hours 500 mg-1 g every 12 hours

0-4 (hemodialysis patients) 500 mg every 48 hours or 250 every 24 hours 500 mg-1 g every 48 hours or 500 mg every 24 hours

Patients on hemodialysis do not need an additional dose, but the drug should be administered (according to the table above) at the end of the hemodialysis session.

To prepare a solution for intravenous injections, the contents of the vial (1 g) are dissolved with 3 ml of sterile water for injection.

To prepare a solution for IV injections, the contents of the vial (1 g) are dissolved with 10 ml of sterile water for injection.
The prepared solution can be injected directly into the vein, or through the cannula for the administration of parenteral fluids. For intravenous administration, the previously reconstituted solution is then diluted in 50-100 ml of 0.9% sodium chloride solution, 5% or 10% dextrose (glucose) solution, 5% dextrose solution and 0.9%, 0.45% or 0.2% sodium chloride solution, in Ringer's and Ringer's lactate solution, 5% sodium bicarbonate solution.

The most frequent (more than 1%, but less than 5%):

Allergic reactions: rash, itching, fever.

On the part of the hepatobiliary system: a transient increase in the activity of alanine aminotransferase (ALT), aspartate aminotransferase (ACT) and alkaline phosphatase (AFP).

On the part of the organs of hematopoiesis: transient eosinophilia, thrombocytosis, false-positive test of Coombs.

Reactions at the injection site: burning, inflammation of the subcutaneous tissue, phlebitis (with iv introduction), pain, densification, painful pressure, paresthesia.

Less frequent (less than 1%):

Allergic reactions: numbness and anaphylaxis.

From the hepatobiliary system: increased bilirubin in the blood.

From the genitourinary system: a transient increase in blood urea nitrogen and creatinine;
On the part of the organs of hematopoiesis: anemia (including hemolytic), leukopenia, neutropenia, thrombocytopenia.

From the digestive system: diarrhea, nausea, vomiting, pseudomembranous colitis.


- hypersensitivity (including to other beta-lactam antibiotics);

- Infant age (up to 6 months).

With caution: renal failure, pseudomembranous colitis associated with the use of antibacterial drugs, pregnancy, lactation.


With caution in pregnancy and lactation.


With caution in kidney failure.


Contraindicated for children up to 6 months.


Patients with penicillin allergy may have a cross-sensitivity to cephalosporin antibiotics.

If a severe and prolonged diarrhea occurs during or after treatment, the diagnosis of pseudomembranous colitis should be ruled out, which requires immediate discontinuation of the drug and the appropriate treatment.

Like other cephalosporins ceftizoxime is inactive against Chlamydia trachomatis, therefore, in the case of treatment of infectious-inflammatory diseases of the pelvic organs, when one of the pathogens suspected Chlamydia trachomatis, it is necessary to add antibiotics active against this pathogen.

During the treatment period, it is necessary to periodically monitor the function of the kidneys.

Before starting treatment with ceftizoxime, a laboratory test should be performed to establish the type of pathogen and its sensitivity;
treatment with ceftizoxime may be initiated before the results of these studies are obtained, but should be subsequently adjusted in accordance with the results obtained. In the case of severe infections, ceftizoxime can be used in combination with aminoglycosides.
After dilution, the drug can be stored at room temperature for 7 hours, in the refrigerator - 48 hours. The reconstituted solution can acquire a yellowish color, which does not affect its activity.

Impact on the ability to drive vehicles and manage mechanisms

Studies on the effect of the drug on the ability to drive vehicles and work with mechanisms have not been conducted.


There have been no cases of overdose to date.


When used simultaneously with other cephalosporins and aminoglycosides, the risk of nephrotoxicity increases.

Pharmaceutically incompatible with other medicines (only solvents listed in the section "Dosing and Administration" should be used to reconstitute the drug).


On prescription.


In a dry, protected from light place at a temperature of no higher than 25 ° C.
Keep out of the reach of children. Shelf life - 3 years.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!